228 related articles for article (PubMed ID: 18281562)
1. Gefitinib radiosensitizes non-small cell lung cancer cells by suppressing cellular DNA repair capacity.
Tanaka T; Munshi A; Brooks C; Liu J; Hobbs ML; Meyn RE
Clin Cancer Res; 2008 Feb; 14(4):1266-73. PubMed ID: 18281562
[TBL] [Abstract][Full Text] [Related]
2. [Effect and mechanism of gefitinib inhibition on non-small cell lung cancer radiosensitivity of HCC827 and H358 cell lines].
Gao Z; Zhuang L; Chen Y
Zhongguo Fei Ai Za Zhi; 2012 Jun; 15(6):324-31. PubMed ID: 22681918
[TBL] [Abstract][Full Text] [Related]
3. [Effection and mechanism of radiosensitivity of non-small cell lung cancer cell line H358 following gefitinib treatment].
Deng J; Zhuang L; Chen Y
Zhongguo Fei Ai Za Zhi; 2011 Nov; 14(11):841-7. PubMed ID: 22104217
[TBL] [Abstract][Full Text] [Related]
4. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair.
Kang KB; Zhu C; Wong YL; Gao Q; Ty A; Wong MC
Int J Radiat Oncol Biol Phys; 2012 May; 83(1):e43-52. PubMed ID: 22516386
[TBL] [Abstract][Full Text] [Related]
5. p53 enhances gefitinib-induced growth inhibition and apoptosis by regulation of Fas in non-small cell lung cancer.
Rho JK; Choi YJ; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Cancer Res; 2007 Feb; 67(3):1163-9. PubMed ID: 17283151
[TBL] [Abstract][Full Text] [Related]
6. Gefitinib radiosensitizes non-small cell lung cancer cells through inhibition of ataxia telangiectasia mutated.
Park SY; Kim YM; Pyo H
Mol Cancer; 2010 Aug; 9():222. PubMed ID: 20731837
[TBL] [Abstract][Full Text] [Related]
7. Blockage of epidermal growth factor receptor-phosphatidylinositol 3-kinase-AKT signaling increases radiosensitivity of K-RAS mutated human tumor cells in vitro by affecting DNA repair.
Toulany M; Kasten-Pisula U; Brammer I; Wang S; Chen J; Dittmann K; Baumann M; Dikomey E; Rodemann HP
Clin Cancer Res; 2006 Jul; 12(13):4119-26. PubMed ID: 16818713
[TBL] [Abstract][Full Text] [Related]
8. Radiosensitizing effect of YM155, a novel small-molecule survivin suppressant, in non-small cell lung cancer cell lines.
Iwasa T; Okamoto I; Suzuki M; Nakahara T; Yamanaka K; Hatashita E; Yamada Y; Fukuoka M; Ono K; Nakagawa K
Clin Cancer Res; 2008 Oct; 14(20):6496-504. PubMed ID: 18927289
[TBL] [Abstract][Full Text] [Related]
9. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839).
Friedmann B; Caplin M; Hartley JA; Hochhauser D
Clin Cancer Res; 2004 Oct; 10(19):6476-86. PubMed ID: 15475435
[TBL] [Abstract][Full Text] [Related]
10. Blockade of DNA methylation enhances the therapeutic effect of gefitinib in non-small cell lung cancer cells.
Li XY; Wu JZ; Cao HX; Ma R; Wu JQ; Zhong YJ; Feng JF
Oncol Rep; 2013 May; 29(5):1975-82. PubMed ID: 23440266
[TBL] [Abstract][Full Text] [Related]
11. Adenoviral-mediated PTEN expression radiosensitizes non-small cell lung cancer cells by suppressing DNA repair capacity.
Pappas G; Zumstein LA; Munshi A; Hobbs M; Meyn RE
Cancer Gene Ther; 2007 Jun; 14(6):543-9. PubMed ID: 17431403
[TBL] [Abstract][Full Text] [Related]
12. Targeting of AKT1 enhances radiation toxicity of human tumor cells by inhibiting DNA-PKcs-dependent DNA double-strand break repair.
Toulany M; Kehlbach R; Florczak U; Sak A; Wang S; Chen J; Lobrich M; Rodemann HP
Mol Cancer Ther; 2008 Jul; 7(7):1772-81. PubMed ID: 18644989
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels.
Helfrich BA; Raben D; Varella-Garcia M; Gustafson D; Chan DC; Bemis L; Coldren C; Barón A; Zeng C; Franklin WA; Hirsch FR; Gazdar A; Minna J; Bunn PA
Clin Cancer Res; 2006 Dec; 12(23):7117-25. PubMed ID: 17145836
[TBL] [Abstract][Full Text] [Related]
14. Radiosensitivity enhancement by combined treatment of celecoxib and gefitinib on human lung cancer cells.
Park JS; Jun HJ; Cho MJ; Cho KH; Lee JS; Zo JI; Pyo H
Clin Cancer Res; 2006 Aug; 12(16):4989-99. PubMed ID: 16914589
[TBL] [Abstract][Full Text] [Related]
15. [Effect of gefitinib on radiosensitivity of gastric cancer cell lines].
Cao WG; Ma T; Li JF; Li H; Ji YB; Chen XH; Liu BY; Jin YN
Ai Zheng; 2007 Dec; 26(12):1330-5. PubMed ID: 18076795
[TBL] [Abstract][Full Text] [Related]
16. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.
Mukohara T; Engelman JA; Hanna NH; Yeap BY; Kobayashi S; Lindeman N; Halmos B; Pearlberg J; Tsuchihashi Z; Cantley LC; Tenen DG; Johnson BE; Jänne PA
J Natl Cancer Inst; 2005 Aug; 97(16):1185-94. PubMed ID: 16106023
[TBL] [Abstract][Full Text] [Related]
17. Enhancement of tumor radioresponse by combined treatment with gefitinib (Iressa, ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, is accompanied by inhibition of DNA damage repair and cell growth in oral cancer.
Shintani S; Li C; Mihara M; Terakado N; Yano J; Nakashiro K; Hamakawa H
Int J Cancer; 2003 Dec; 107(6):1030-7. PubMed ID: 14601066
[TBL] [Abstract][Full Text] [Related]
18. Non-small-cell lung cancers with kinase domain mutations in the epidermal growth factor receptor are sensitive to ionizing radiation.
Das AK; Sato M; Story MD; Peyton M; Graves R; Redpath S; Girard L; Gazdar AF; Shay JW; Minna JD; Nirodi CS
Cancer Res; 2006 Oct; 66(19):9601-8. PubMed ID: 17018617
[TBL] [Abstract][Full Text] [Related]
19. Bevacizumab radiosensitizes non-small cell lung cancer xenografts by inhibiting DNA double-strand break repair in endothelial cells.
Gao H; Xue J; Zhou L; Lan J; He J; Na F; Yang L; Deng L; Lu Y
Cancer Lett; 2015 Aug; 365(1):79-88. PubMed ID: 25982206
[TBL] [Abstract][Full Text] [Related]
20. Enhancement of Radiosensitivity by Eurycomalactone in Human NSCLC Cells Through G₂/M Cell Cycle Arrest and Delayed DNA Double-Strand Break Repair.
Dukaew N; Konishi T; Chairatvit K; Autsavapromporn N; Soonthornchareonnon N; Wongnoppavich A
Oncol Res; 2020 Mar; 28(2):161-175. PubMed ID: 31727206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
